Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit www.ambrx.com. Ambrx routinely posts information that may be important to investors on its website.
Company profile
Ticker
AMAM
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ambrx Biopharma Inc.
SEC CIK
Corporate docs
Subsidiaries
Shanghai Ambrx Biopharma Company Limited • Biolaxy Pharmaceutical • Ambrx Australia Pty Limited • Ambrx Inc. ...
IRS number
571147346
AMAM stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
7 Mar 24
15-12G
Securities registration termination
23 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Oct 23
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Oct 23
25-NSE
Exchange delisting
12 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
10 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
Transcripts
Latest ownership filings
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G
HOPU Reunion Co Ltd
10 Oct 23
SC 13G
Paradigm Biocapital Advisors LP
25 Sep 23
4
Bihua Chen
19 Sep 23
4
MARGARET DALESANDRO
6 Sep 23
3
MARGARET DALESANDRO
6 Sep 23
4
Daniel J. O'Connor
7 Jul 23
4
Sonja Nelson
7 Jul 23
4
Andrew Aromando
7 Jul 23
4
Abhishek Trehan
28 Jun 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 228.93 mm | 228.93 mm | 228.93 mm | 228.93 mm | 228.93 mm | 228.93 mm |
Cash burn (monthly) | (no burn) | (no burn) | 6.39 mm | 2.93 mm | 224.33 k | 1.14 mm |
Cash used (since last report) | n/a | n/a | 74.88 mm | 34.37 mm | 2.63 mm | 13.32 mm |
Cash remaining | n/a | n/a | 154.05 mm | 194.56 mm | 226.30 mm | 215.61 mm |
Runway (months of cash) | n/a | n/a | 24.1 | 66.3 | 1008.8 | 189.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 51 |
Opened positions | 19 |
Closed positions | 5 |
Increased positions | 12 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 754.91 bn |
Total shares | 188.40 mm |
Total puts | 243.90 k |
Total calls | 342.60 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
HOPU Reunion | 38.95 mm | $351.74 mm |
WuXi PharmTech Healthcare Fund I | 29.27 mm | $264.29 mm |
Venrock Healthcare Capital Partners III | 26.74 mm | $74.34 mm |
D. E. Shaw & Co | 22.05 mm | $276.51 mm |
Darwin Global Management | 16.69 mm | $274.69 bn |
Artal International S.C.A. | 15.07 mm | $0.00 |
Cormorant Asset Management | 9.62 mm | $158.28 bn |
HBM Healthcare Investments | 8.40 mm | $0.00 |
D. E. Shaw & Co. | 4.02 mm | $66.10 bn |
Commodore Capital | 3.18 mm | $52.26 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Sep 23 | Cormorant Asset Management | Ordinary Shares | Buy | Acquire P | Yes | No | 9.2447 | 751,233 | 6.94 mm | 69,465,823 |
15 Sep 23 | Cormorant Asset Management | Ordinary Shares | Buy | Acquire P | Yes | No | 9.0479 | 1,401,505 | 12.68 mm | 68,714,590 |
1 Sep 23 | Dalesandro Margaret | Ordinary Shares | Grant | Acquire A | No | No | 0 | 70,833 | 0.00 | 70,833 |
1 Sep 23 | Dalesandro Margaret | Ordinary Shares | Grant | Acquire A | No | No | 0 | 125,000 | 0.00 | 125,000 |
27 Jun 23 | Darwin Global Management | American Depository Shares ("ADSs") Ordinary Shares | Buy | Acquire P | Yes | No | 13.93 | 5,384,063 | 75.00 mm | 16,688,636 |
7 Jun 23 | Janet Loesberg | Ordinary Shares | Grant | Acquire A | No | No | 0 | 85,000 | 0.00 | 85,000 |